HIV-Associated Nephropathy Market 2022
Nanotech has already made inroads into the healthcare vertical. Scientists, by the end of the year 2021, did create xenobiotics (tiny organic robots) that are capable of self-replicating. Nanotech involves the usage of nanoscale objects and materials like biocompatible nanomaterials, nanorobots, or even nanoelectronic devices to serve exclusive medical purposes like diagnosing/treating living organisms. The HIV-Associated Nephropathy Market would go nan ways in the next 10 years.
Human immunodeficiency virus (HIV) affects kidney function in patients. HIV-positive patients are at increased risk for a variety of renal disorders. HIV-associated nephropathy (HIVAN) is also one of the kidney disorder which affects HIV-positive patients.
Get Free Sample Copy of This Report@https://www.persistencemarketresearch.com/samples/27577
HIV-associated nephropathy (HIVAN) was first described in 1984 as the complication of acquired immune deficiency syndrome. HIV-associated nephropathy (HIVAN) starts with a large amount of protein in the urine and progresses rapidly to total kidney failure.
Antiretroviral therapy preserved kidney function in patients with HIV. Treatment with Antiretroviral drugs reduced the risk of the HIV-associated nephropathy. HIV Medicine Association and Infectious Diseases Society of America recommended the use of antiretroviral drugs (ART) for patients with HIV-associated nephropathy. In the various clinical studies, it’s suggested that corticosteroids and ACE inhibitors are also beneficial for the treatment of HIV-associated nephropathy.
The global market for HIV-associated nephropathy is expected to witness significant and continuous growth over the forecast period due to the rising number of HIV cases. In 2017, estimated 36.9 Mn people are suffered from HIV globally. Government and private organization take initiative to reduce the number of cases of HIV and support HIV treatment.
Request for Table of Content@https://www.persistencemarketresearch.com/toc/27577
These are the major factor expected to propel the growth of the HIV-associated nephropathy market. The program such as UNAIDS’ 90-90-90 is initiated for the prevention and treatment of HIV and associated disorders. Increasing HIV treatment access expected to favors the growth of the HIV-associated nephropathy market.
According to Avert Organization, in 2017, around 59% of all people living with HIV were accessing treatment as compared to past years. Moreover, in 2017, 21.7 Mn people living with HIV were receiving ART therapy which increased by 2.3 Mn from 2016.
However, side effects associated with long-term use of ART expected to restrain the growth of the HIV-associated nephropathy market. Long-term use of ART therapy has been linked to various other diseases such as diabetic nephropathy and focal segmental glomerulosclerosis.
Market Segmentation
By Drug Class
Antiretroviral Drugs
Protease inhibitors
Corticosteroids
Angiotensin-converting enzyme (ACE) inhibitors
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Pre-Book This Report@https://www.persistencemarketresearch.com/checkout/27577
Region
North America
Latin America
Europe
Asia Pacific
Middle East & Africa
About PersistenceMarketResearch:
PersistenceMarketResearch is an esteemed company with a reputation of serving clients across domains of information technology (IT), healthcare, and chemicals. Our analysts undertake painstaking primary and secondary research to provide a seamless report with a 360 degree perspective. Data is compared against rep/uted organizations, trustworthy databases, and international surveys for producing impeccable reports backed with graphical and statistical information.
Media Contact:
Persistence Market Research
305 Broadway,7th Floor New York City, NY 10007 United States
Call +1-646-568-7751
Call +1 800-961-0353